DEERFIELD, Ill., May 20, 2025
/PRNewswire/ -- "Hemopatch Sealing Hemostat represents
a significant development from Baxter, and introducing the
room-temperature variant highlights our ongoing dedication to
innovation in Tissue Management," stated Steve Wallace, President of Advanced Surgery at
Baxter.
Building on a decade of market success, Baxter is excited to
unveil Hemopatch Sealing Hemostat which now offers the
convenience of room-temperature storage and an extended shelf life
of 3 years.
The performance of Hemopatch Sealing Hemostat involves
the interaction of two components that can create rapid and lasting
hemostasis by sealing off the bleeding surface. The white,
tissue-facing side of Hemopatch Sealing Hemostat is covered
with a thin layer of NHS-PEG. The NHS-PEG, when in contact with
blood or other body fluids forms a hydrogel which enhances its
adhering properties and seals the tissue surface. In contact with
blood, collagen induces aggregation of platelets. Platelets deposit
in large numbers on the collagen structure, degranulate, and
release coagulation factors that, together with plasma factors,
enable the formation of fibrin. The structure of Hemopatch
Sealing Hemostat provides a three-dimensional matrix that readily
absorbs fluids, and provides additional mechanical strengthening of
the clot. Preclinical studies suggest that resorption and
replacement with host tissue occurs in approximately 6 – 8 weeks
with little tissue reaction.
The rate of resorption and replacement with host tissue can be
longer as it depends on several factors, including the amount of
product left in situ and the site of use.
Hemopatch Sealing Hemostat has multiple clinical
benefits, such as sealing tissue, stopping and preventing leaks,
fast and effective hemostasis within 2 minutes, and being absorbed
and replaced by host tissue.
For Hemopatch Sealing Hemostat Indications and Important
Risk Information watch the video at the top of this article or
visit https://advancedsurgery.baxter.eu/hemopatch#isi
For more information on Hemopatch Sealing Hemostat,
visit: https://advancedsurgery.baxter.eu/hemopatch
Manufacturer:
Baxter Healthcare SA
Thurgauerstrasse 130 Glattbrugg,
ZÜRICH, 8152 Switzerland
Class of Device: III
CE 0123
This content is intended solely for healthcare professionals and
should not be interpreted as medical advice. Please consult with a
qualified healthcare provider for any health concerns.
Hemopatch Sealing Hemostat is approved for use only
in selected countries. For specific information on the availability
and regulatory status of Hemopatch Sealing Hemostat RT in
your country, we recommend contacting your local Baxter Healthcare
sales representative.
Video -
https://mma.prnewswire.com/media/2687592/EMA_HemopatchCustomer.mp4
Logo -
https://mma.prnewswire.com/media/2687591/Baxter_International_Inc_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/baxter-launches-hemopatch-sealing-hemostat-a-room-temperature-collagen-pad-approved-for-hemostasis-and-sealing-suitable-for-open-surgery-and-minimally-invasive-surgical-procedures-mis-302458074.html
